Sequence Towards Remission in Depression

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01628783

Acronym

STRIDE

Enrollment

Registered

2012-06-27

Start date

2012-06-30

Completion date

2015-10-31

Last updated

2012-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression, emotional processing, fMRI, autobiographic memory, moderator of treatment response, mediator of treatment response

Brief summary

In this study the investigators use clinical, biological and imaging markers to develop predictive markers for remission from depression. The investigators compare individuals who have received placebo to individuals who have received 10 mg of escitalopram for one week. In this double-blind, randomized study the investigators a) compare the groups to observe the short-term effects of escitalopram and b) study the predictive value of these observations with respect to remission. Measures include, but are not restricted to, limbic emotional reactivity as assessed by fMRI, emotional processing, emotional memory, autobiographical memory.

Interventions

DRUGescitalopram 10 mg

orally once daily

DRUGPlacebo

once daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Major depressive disorder with current major depressive episode according to a SCID-I/P interview * Montgomery-Åsberg depression rating score 15-30 * Age 18-60

Exclusion criteria

* Borderline, schizoid or schizotypal personality, bipolar or any psychotic disorder * Primary diagnosis is anxiety disorder: 300.00, .01, .02, .21, .22, .29, .23, .3, 309.81, 308.3, 293.89 * Significant current suicidal ideation, or history of a suicide attempt * Lifetime substance dependence; Last-year substance abuse; Last month over 24/16 standard doses of alcohol/week; Lifetime use of illicit substances \> x5; Any illicit substance use in last month * Depressive disorder due to medical condition or chemical substance * Antidepressant medication use in last 4 months * Severe, unstable somatic illness * Use of antipsychotics, mood stabilizers, systemic corticosteroids, β-blockers or daytime benzodiazepines (a small dose of ≤10mg zolpidem once daily is permissible)

Design outcomes

Primary

Measure	Time frame
Montgomery-Åsberg rating scale	7 weeks

Countries

Finland

Contacts

Primary ContactJesper Ekelund, MD-PhD

Jesper.Ekelund@helsinki.fi+358503317987

Backup ContactErkki Isometsa, MD-PhD

Erkki.Isometsa@helsinki.fi+35894711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026